StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)

Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –

Earnings

Protalix BioTherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 17, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
– on a year earlier
EPS, Q3 FY2026
$0.05
$0.03 a year earlier
Latest guidance
Issued
Nov 10, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Protalix BioTherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 17, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––$0.05Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open––$0.05Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open––$0.22Release
Q4 FY2025ended Dec 31, 2025Mar 18, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open$17.90M–$0.03Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open––$0.00Release
Q1 FY2025ended Mar 31, 2025May 9, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open––$0.03Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024before the open––-$0.03Release
Q1 FY2024ended Mar 31, 2024May 10, 2024before the open––-$0.06Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Protalix BioTherapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$78.00M – $83.00M$78.00M – $83.00MRaisedAug 12, 2026
Total revenuesFY2026$78.00M – $83.00M–NewNov 10, 2026

Guidance history

Every forecast Protalix BioTherapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026Total revenuesFY2026$78.00M – $83.00MNew
Aug 12, 2026Total revenueFY2026$78.00M – $83.00MRaised
Aug 12, 2026revenues from sales of Elfabrio ® without milestonesFY2026$33.00M – $35.00MLowered
Aug 12, 2026revenues from sales of Elelyso ®FY2026$20.00M – $23.00MLowered
May 13, 2026Total revenueFY2026$78.00M – $83.00MRaised
May 13, 2026Full-year 2026 revenues from sales of Elfabrio without milestonesFY2026$33.00M – $35.00MLowered
May 13, 2026Full-year 2026 revenues from sales of ElelysoFY2026$20.00M – $23.00MLowered
Mar 18, 2026Total revenueFY2026$78.00M – $83.00MNew
Mar 18, 2026revenues from sales of Elfabrio without milestonesFY2026$33.00M – $35.00MLowered
Mar 18, 2026revenues from sales of ElelysoFY2026$20.00M – $23.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Protalix BioTherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
    Results
  2. Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
    Results
  3. C O R P O R A T E P R E S E N T A T I O N
    Update
  4. Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
    Results
  5. Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
    Results
  6. Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio ® (pegunigalsidase alfa)
    News
  7. C O R P O R A T E P R E S E N T A T I O N
    Update
  8. Chiesi Global Rare Diseases and Protalix BioTherapeutics
    News
  9. Protalix BioTherapeutics Letter to Stockholders
    Update
  10. Third Quarter 2025 Financial and Business Results
    Results
  11. 8-K exhibit EX-99.1
    News
  12. C O R P O R A T E P R E S E N T A T I O N
    Update
  13. Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of
    Update
  14. Second Quarter 2025 Financial and Business Results
    Results
  15. Protalix BioTherapeutics Reports First Quarter 2025
    Results

See a number that looks wrong?